Login to Your Account



Other News To Note


Monday, October 8, 2012
• Deciphera Pharmaceuticals LLC, of Lawrence, Kan., said it plans to transition from an oncology discovery company to an oncology drug development company and will focus its resources on the continued development of rebastinib and DCC-2701, two drugs discovered using its switch pocket kinase inhibitor technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription